Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Total Receivables: ¥836 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
65 GF Score
Price ¥15.42
GF Value ¥13.72
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Total Receivables?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -6.94% 65 Total Receivables is ¥836 Mil as of Mar. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 65/100 and a GF Value™ of ¥13.72 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Jiangsu Lianhuan Pharmaceutical Co's Total Receivables for the quarter that ended in Mar. 2026 was ¥836 Mil.

Jiangsu Lianhuan Pharmaceutical Co Total Receivables Related Terms

Jiangsu Lianhuan Pharmaceutical Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Total Receivables Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 530.08 584.97 595.44 631.05 773.41

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 676.27 699.31 831.63 773.41 835.52
SHSE:600513
65GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ¥836 Mil mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Total Receivables of ¥836 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors.
Is Jiangsu Lianhuan Pharmaceutical Co's Total Receivables too high?
Jiangsu Lianhuan Pharmaceutical Co's current Total Receivables is ¥836 Mil. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Total Receivables compare to ZTS and UTHR?
Jiangsu Lianhuan Pharmaceutical Co's Total Receivables of ¥836 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Total Receivables is ¥836 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥15.42 — trading 12.4% above its estimated fair value. The current Total Receivables is ¥836 Mil. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Total Receivables is ¥836 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • Total Receivables: ¥836 Mil
  • GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score

Get the complete analysis for SHSE:600513

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.42
Price
¥13.72
GF Value